Sun08252019

Robins Global News & Noticias



  • Gaming Chair Review
    Gaming Chair Review
  • Writing Service Review
    Writing Service Review
  • Youtube Marketing Guide
    Youtube Marketing Guide
  • Slot Game Review
    Slot Game Review
  • Download TV Series
    Download TV Series
  • All Elite Wrestling
    All Elite Wrestling

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS


NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS). Such investors are advised to contact Robert S. Willoughby at @pomlaw.com">This email address is being protected from spambots. You need JavaScript enabled to view it. or 888-476-6529, ext. 9980.
The investigation concerns whether Adamas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]In January 2018, Adamas completed a secondary public offering (“SPO”), issuing approximately 3 million shares of common stock priced at $41.50 per share.  In October 2018, Merrill Lynch released a study which cast serious doubt on the ability of Gocovri, Adamas’s treatment for dyskinesia in Parkinson’s disease patients treated with levodopa therapy, to achieve a sizeable market share and emphasized that Adamas had failed to include critical information.  In March 2019, Adamas backtracked on prior issued growth estimates and no longer made predictions regarding Gocovri’s ability to achieve a sizeable market share.  Adamas’s stock price has fallen sharply since the SPO and now trades well below the offering price.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.


Posted: 2019-06-12 23:05:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Coliseum development finalized; City Council to review plans

Fri, 02 Aug 2019 05:05:00 GMT

Since Stoney introduced the Navy Hill Redevelopment plan 21 months ago, the City, Richmond-based community leaders of the nonprofit NH Foundation on behalf of the Navy Hill ... buses,” interim CEO of ...

Sipp chief took out £1m ahead of collapse

Wed, 03 Jul 2019 02:14:00 GMT

It is facing court action from 141 investors and a further 500 claims through the Financial Ombudsman Service ... The only uncertainty cited by the company in the accounts was the ongoing court case ...

ADMS INVESTORS NOTICE: Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc.

Mon, 17 Jun 2019 16:52:00 GMT

SAN FRANCISCO--(BUSINESS WIRE)--Jun. 17, 2019-- The law firm of Lieff Cabraser Heimann & Bernstein, LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the ...

ADMS INVESTORS NOTICE:Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc.

Mon, 17 Jun 2019 10:54:00 GMT

The law firm of Lieff Cabraser Heimann & Bernstein, LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) ADMS, +3.63%, including investors who ...

ADMS INVESTORS NOTICE: Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc.

Sun, 16 Jun 2019 22:54:00 GMT

SAN FRANCISCO--(BUSINESS WIRE)-- The law firm of Lieff Cabraser Heimann & Bernstein, LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") ...

Related News Story Videos From Youtube

Wall Street Vs. Registered Investment Advisor


Related Videos On: Wall Street Vs. Registered Investment Advisor


Fall 2017 Provost's Lecture Deputy Surgeon General Rear Admiral Sylvia Trent-Adams, Ph.D


Related Videos On: Fall 2017 Provost's Lecture Deputy Surgeon General Rear Admiral Sylvia Trent-Adams, Ph.D


Question 5 - Raymond Huo to the on Behalf of Minister of Housing and Urban Development


Related Videos On: Question 5 - Raymond Huo to the on Behalf of Minister of Housing and Urban Development


HSFS: Why and How Government Leaders Can Help - Eric L. Adams


Related Videos On: HSFS: Why and How Government Leaders Can Help - Eric L. Adams


Long Term Disability- UNUM Class Action Lawsuit


Related Videos On: Long Term Disability- UNUM Class Action Lawsuit






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.